Weight Gain and Adipose Tissue
Primary Purpose
Obesity
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
overfeeding induced weight gain
Sponsored by
About this trial
This is an interventional basic science trial for Obesity
Eligibility Criteria
Inclusion Criteria
- Age: 18 to 40 (inclusive) years
- BMI 18.5 <30 kg/m2
- Gender: Both males and females will be allowed to participate in the study
- Predominantly sedentary
- Absence of any chronic medical conditions other than seasonal or environmental allergies
- On no prescription medications other than second generation antihistamines (cetirizine , Fexofenadine, Desloratadine, Loratadine, etc), oral contraceptive pills, or intrauterine devices
- Not a current smoker or tobacco user
- Not pregnant or breast feeding and not intending to become pregnant or breast feed
- Lean (low body fat mass) (body fat content ≤ 25% for men, < 35% for women) n=7; Obese (high body fat mass) (body fat content >25% for men, ≥ 35% for women) n=7
- Ability to provide written informed consent
Exclusion Criteria
- Vulnerable study population will be excluded
- Presence of chronic diseases such as diabetes, and cardiovascular disease
- Pregnancy
- Anemic (hemoglobin <13.5 g/dL for men and <12.0 g/dL for women)
- Postmenopausal
- Smoking
- Use of chronic Medications (aspirin, statin, anti-inflammatory drugs)
- Subjects found to have significant sleep disorders will be excluded
- Dietary restrictions including lactose intolerance, and vegan diet
- Eating disorders that may interfere with weight gain and weight loss
Sites / Locations
- Mayo Clinic in Rochester
- Mayo Clinic
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
Lean
Obese
Arm Description
Lean individuals are defined as having body fat content less or equal to 25% in men and less than 35% for women. Overfeeding induced weight gain and subsequent weight loss
obese individuals are defined as having body fat content more than 25% in men and more than 35% for women. Overfeeding induced weight gain and subsequent weight loss
Outcomes
Primary Outcome Measures
Change from baseline in adipose tissue inflammation by 8 week of modest weight gain followed by 8 week of weight loss.
Adipose tissue inflammation will be measures by RTPCR and Western Blot. These will be presented as ratio to endogenous house keeping gene.
Secondary Outcome Measures
Change from baseline in blood pressure by 8 week of modest weight gain followed by 8 weeks of weight loss.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02703766
Brief Title
Weight Gain and Adipose Tissue
Official Title
Pilot Study to Examine the Effects of Weight Gain on Adipose Tissue
Study Type
Interventional
2. Study Status
Record Verification Date
January 2019
Overall Recruitment Status
Completed
Study Start Date
April 2016 (undefined)
Primary Completion Date
March 2018 (Actual)
Study Completion Date
December 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Mayo Clinic
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study aims to examine the role of weight gain in adipose tissue immune cell influx and development of obesity related cardiometabolic disorders. Adipose tissue-mediated chronic systemic inflammation is implicated in the development of cardiometabolic disorders in obesity. Therefore, resolution of adipose tissue inflammation may be key to ameliorating obesity-associated dyslipidemia, insulin-resistance, and cardiovascular disease. Proinflammatory cytokines contribute to the initial influx of immune cells into adipose tissue during weight gain. However, mechanisms regulating these cytokines in the adipose tissue milieu and the effects of weight gain on adipose tissue are not completely understood.
The study proposes to investigate the molecular events contributing to increased infiltration of macrophages and T-cells into adipose tissue during weight gain. The central hypothesis is that in lean subjects (with low body fat mass), healthy fat gain which is associated with decreased expression of proinflammatory cytokines. However, in obesity (high body fat mass), adipose tissue is altered, which permits increased expression of inflammatory cytokines and further fat gain results in influx of immune cells. To test the hypothesis, adipose tissue from well characterized lean (control, with low body fat) and obese individuals (with high body fat) at baseline and after a modest 5% weight gain will be used. Adipose tissue samples after subsequent weight loss will also be examined.
For this study, obesity will be defined by body composition rather than body mass index (BMI), as several studies have shown that BMI does not adequately define obesity and several individuals with normal BMI may indeed have high body fat mass. Individuals with body fat content ≤25% for men, & <35% for women) will be considered lean and individuals with body fat content >25% for men, ≥35% for women will be considered obese.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
14 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Lean
Arm Type
Active Comparator
Arm Description
Lean individuals are defined as having body fat content less or equal to 25% in men and less than 35% for women.
Overfeeding induced weight gain and subsequent weight loss
Arm Title
Obese
Arm Type
Experimental
Arm Description
obese individuals are defined as having body fat content more than 25% in men and more than 35% for women.
Overfeeding induced weight gain and subsequent weight loss
Intervention Type
Behavioral
Intervention Name(s)
overfeeding induced weight gain
Primary Outcome Measure Information:
Title
Change from baseline in adipose tissue inflammation by 8 week of modest weight gain followed by 8 week of weight loss.
Description
Adipose tissue inflammation will be measures by RTPCR and Western Blot. These will be presented as ratio to endogenous house keeping gene.
Time Frame
16-20 weeks
Secondary Outcome Measure Information:
Title
Change from baseline in blood pressure by 8 week of modest weight gain followed by 8 weeks of weight loss.
Time Frame
16-20 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria
Age: 18 to 40 (inclusive) years
BMI 18.5 <30 kg/m2
Gender: Both males and females will be allowed to participate in the study
Predominantly sedentary
Absence of any chronic medical conditions other than seasonal or environmental allergies
On no prescription medications other than second generation antihistamines (cetirizine , Fexofenadine, Desloratadine, Loratadine, etc), oral contraceptive pills, or intrauterine devices
Not a current smoker or tobacco user
Not pregnant or breast feeding and not intending to become pregnant or breast feed
Lean (low body fat mass) (body fat content ≤ 25% for men, < 35% for women) n=7; Obese (high body fat mass) (body fat content >25% for men, ≥ 35% for women) n=7
Ability to provide written informed consent
Exclusion Criteria
Vulnerable study population will be excluded
Presence of chronic diseases such as diabetes, and cardiovascular disease
Pregnancy
Anemic (hemoglobin <13.5 g/dL for men and <12.0 g/dL for women)
Postmenopausal
Smoking
Use of chronic Medications (aspirin, statin, anti-inflammatory drugs)
Subjects found to have significant sleep disorders will be excluded
Dietary restrictions including lactose intolerance, and vegan diet
Eating disorders that may interfere with weight gain and weight loss
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Virend Somers, MD, PhD
Organizational Affiliation
Mayo Clinic
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mayo Clinic in Rochester
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States
Facility Name
Mayo Clinic
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
Weight Gain and Adipose Tissue
We'll reach out to this number within 24 hrs